Sodium–glucose cotransporter 2 inhibitors reduce myocardial infarct size in preclinical animal models of myocardial ischaemia–reperfusion injury: a meta-analysis

Aims/hypothesis Large cardiovascular outcome trials demonstrated that the cardioprotective effects of sodium–glucose cotransporter 2 (SGLT2) inhibitors might reach beyond glucose-lowering action. In this meta-analysis, we sought to evaluate the potential infarct size-modulating effect of SGLT2 inhib...

Full description

Saved in:
Bibliographic Details
Published in:Diabetologia 2021-04, Vol.64 (4), p.737-748
Main Authors: Sayour, Alex Ali, Celeng, Csilla, Oláh, Attila, Ruppert, Mihály, Merkely, Béla, Radovits, Tamás
Format: Article
Language:English
Subjects:
Animal models
Animals
Cardiovascular Agents - pharmacology
Clinical trials
Diabetes
Diabetes mellitus
Disease Models, Animal
Glucose
Human Physiology
Internal Medicine
Ischemia
Medicine
Medicine & Public Health
Meta-analysis
Metabolic Diseases
Myocardial infarction
Myocardial Infarction - metabolism
Myocardial Infarction - pathology
Myocardial Infarction - prevention & control
Myocardial Reperfusion Injury - metabolism
Myocardial Reperfusion Injury - pathology
Myocardial Reperfusion Injury - prevention & control
Myocardium - metabolism
Myocardium - pathology
Na+/glucose cotransporter
Placebos
Reperfusion
Rodents
Sodium-Glucose Transporter 2 Inhibitors - pharmacology
Translational Research, Biomedical
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Aims/hypothesis Large cardiovascular outcome trials demonstrated that the cardioprotective effects of sodium–glucose cotransporter 2 (SGLT2) inhibitors might reach beyond glucose-lowering action. In this meta-analysis, we sought to evaluate the potential infarct size-modulating effect of SGLT2 inhibitors in preclinical studies. Methods In this preregistered meta-analysis (PROSPERO: CRD42020189124), we included placebo-controlled, interventional studies of small and large animal models of myocardial ischaemia–reperfusion injury, testing the effect of SGLT2 inhibitor treatment on myocardial infarct size (percentage of area at risk or total area). Standardised mean differences (SMDs) were calculated and pooled using random-effects method. We evaluated heterogeneity by computing Τ 2 and I 2 values. Meta-regression was performed to explore prespecified subgroup differences according to experimental protocols and their contribution to heterogeneity was assessed (pseudo- R 2 values). Results We identified ten eligible publications, reporting 16 independent controlled comparisons on a total of 224 animals. Treatment with SGLT2 inhibitor significantly reduced myocardial infarct size compared with placebo (SMD = −1.30 [95% CI −1.79, −0.81], p  
ISSN:0012-186X
1432-0428
DOI:10.1007/s00125-020-05359-2